The Best Website Builder for Biotech, and When to Skip One

Every biotech founder eventually types some version of "best website builder for biotech" into Google. It is a reasonable question with an unhelpful answer, because the platforms are far more similar than the marketing suggests, and the thing that sinks biotech sites is almost never the platform.

What sinks them is that nobody decided, before the build started, how much scientific weight the site has to carry. A page describing a service business carries none. A page describing a bispecific antibody carries a great deal. The same builder that is perfectly adequate for the first is a liability for the second, and the cost of the mistake does not show up until a partner's scientific team reads the site.

The question that decides everything

Before comparing platforms, answer this: if a reviewer with a PhD in your field reads this site closely, how much of it has to withstand that reading?

If the answer is "the homepage headline and not much else", any builder on this list will do, and you should pick the one you can edit fastest. If the answer includes a mechanism of action, a pipeline table, assay performance, or a claim about what your platform does that a competitor would dispute, the platform stops being the constraint and the person writing the content becomes the constraint.

That is the whole decision. Everything below is detail.

WordPress

The most capable option and the most demanding one. WordPress will do anything you need: custom post types for a pipeline, structured data for publications, a real content model that separates a programme from the pages that describe it. It also needs someone to own updates, plugin conflicts and security, which is a real recurring cost that founders routinely forget to budget.

Choose it when the site has genuine structure, meaning content that repeats with fields rather than a handful of one-off pages. A pipeline of eleven programmes belongs in a content model. A pipeline of two does not.

Webflow

Closer to designing in a browser than filling in a template, which makes it good for the figure-heavy layouts biotech actually needs. Mechanism diagrams, annotated assay charts and staged pipeline visuals are easier to place precisely here than in a theme-driven builder.

The trade is that editing is less obvious to a non-designer than WordPress or Squarespace, so the person who built it tends to stay involved. For a small team that is often fine. For a team that wants to change copy weekly without asking anyone, it is friction.

Wix and Squarespace

Both get a credible site live quickly, and for a pre-seed company with a thesis, two founders and no data to show, quickly is the correct optimisation. Squarespace in particular produces a restrained, professional result without design input, which matters when the alternative is a site that looks improvised.

Where both struggle is anything structured. Pipeline tables, publication lists and figure-heavy explanatory pages end up as hand-built one-offs that nobody wants to update, so they go stale. If you expect the site to still be describing your science accurately in eighteen months, notice that these platforms make the accurate thing the effortful thing.

HubSpot

Worth it when the website is downstream of a sales motion, which for biotech usually means tools, reagents, CRO services or diagnostics with a commercial funnel. The CMS is adequate and the reason to be there is the CRM underneath it.

It is the wrong centre of gravity for a therapeutics company whose website exists to be read by investors, partners and prospective scientific hires rather than to capture leads. Paying for marketing automation to publish eight pages is a poor trade.

The honest version of the advice

A builder is the right answer more often than agencies admit. If your site is a homepage, a team page, a short pipeline and a contact form, and the science can be stated in language your own board already uses, pick Squarespace or Webflow and spend the saved money on something that compounds.

A builder stops being the right answer at a specific and recognisable point: when the accuracy of the content starts costing you time. The signal is not aesthetic. It is you and your CSO spending three hours correcting a description of your own mechanism, twice, and still shipping something you would not put in a deck. At that point you are no longer paying for a website. You are paying with the scarcest thing in a small company, which is senior scientific attention.

That is the only real argument for a specialist build, and it does not apply to everyone.

A short checklist before you commit

• Count the structured content. More than roughly five repeating items of any kind, whether programmes, assays or publications, and you want a real content model.
• Name the figure owner. Decide now who draws the mechanism figure and who signs off that it is correct. This is the single most common point of failure.
• Check what you cannot say. If material is unpublished or patent-sensitive, the constraint is editorial, not technical, and no platform helps you.
• Budget the maintenance, not just the build. A site nobody can update is a site that quietly becomes wrong.
• Decide who the reader is. A site written for investors and a site written for customers are different documents. Most biotech sites try to be both and persuade neither.

If you are at the pre-seed stage and want the shortest path to something defensible, the pre-seed biotech website covers what the first version actually has to accomplish. If the constraint is the science rather than the layout, the cost of generalist agencies explains where those hours usually go.